Clinical Significance of Alloantibodies in Hand Transplantation: A Multicenter Study.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 1 3 2019
medline: 20 6 2020
entrez: 1 3 2019
Statut: ppublish

Résumé

Donor-specific antibodies (DSAs) have a strong negative correlation with long-term survival in solid organ transplantation. Although the clinical significance of DSA and antibody-mediated rejection (AMR) in upper extremity transplantation (UET) remains to be established, a growing number of single-center reports indicate their presence and potential clinical impact. We present a multicenter study assessing the occurrence and significance of alloantibodies in UET in reference to immunological parameters and functional outcome. Our study revealed a high prevalence and early development of de novo DSA and non-DSA (43%, the majority detected within the first 3 postoperative y). HLA class II mismatch correlated with antibody development, which in turn significantly correlated with the incidence of acute cellular rejection. Cellular rejections preceded antibody development in almost all cases. A strong correlation between DSA and graft survival or function cannot be statistically established at this early stage but a correlation with a lesser outcome seems to emerge. While the phenotype and true clinical effect of AMR remain to be better defined, the high prevalence of DSA and the correlation with acute rejection highlight the need for optimizing immunosuppression, close monitoring, and the relevance of an HLA class II match in UET recipients.

Sections du résumé

BACKGROUND
Donor-specific antibodies (DSAs) have a strong negative correlation with long-term survival in solid organ transplantation. Although the clinical significance of DSA and antibody-mediated rejection (AMR) in upper extremity transplantation (UET) remains to be established, a growing number of single-center reports indicate their presence and potential clinical impact.
METHODS
We present a multicenter study assessing the occurrence and significance of alloantibodies in UET in reference to immunological parameters and functional outcome.
RESULTS
Our study revealed a high prevalence and early development of de novo DSA and non-DSA (43%, the majority detected within the first 3 postoperative y). HLA class II mismatch correlated with antibody development, which in turn significantly correlated with the incidence of acute cellular rejection. Cellular rejections preceded antibody development in almost all cases. A strong correlation between DSA and graft survival or function cannot be statistically established at this early stage but a correlation with a lesser outcome seems to emerge.
CONCLUSIONS
While the phenotype and true clinical effect of AMR remain to be better defined, the high prevalence of DSA and the correlation with acute rejection highlight the need for optimizing immunosuppression, close monitoring, and the relevance of an HLA class II match in UET recipients.

Identifiants

pubmed: 30817406
doi: 10.1097/TP.0000000000002650
doi:

Substances chimiques

HLA Antigens 0
Isoantibodies 0
Isoantigens 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2173-2182

Auteurs

Erik Berglund (E)

Division of Transplantation Surgery, Department of Transplantation Surgery, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY.

Mette Andersen Ljungdahl (M)

Division of Transplantation Surgery, Department of Transplantation Surgery, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Darko Bogdanović (D)

Division of Transplantation Surgery, Department of Transplantation Surgery, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

David Berglund (D)

Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Sweden.

Jonas Wadström (J)

Division of Transplantation Surgery, Department of Transplantation Surgery, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Jan Kowalski (J)

JK Biostatistics AB, Stockholm, Sweden.

Gerald Brandacher (G)

Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

Dorota Kamińska (D)

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland.

Christina L Kaufman (CL)

Christine M. Kleinert Institute for Hand and Microsurgery, Louisville, KY.

Simon G Talbot (SG)

Division of Plastic Surgery, Brigham and Women's Hospital, Boston, MA.

Kodi Azari (K)

Division of Plastic Surgery, Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Luis Landin (L)

FIBHULP/IdiPaz, Division of Plastic and Reconstructive Surgery, Hospital Universitario "La Paz," Madrid, Spain.

Christoph Höhnke (C)

Division of Plastic and Reconstructive Surgery, Klinikum Memmingen, Memmingen, Germany.
Technical University Munich, München, Germany.

Karen M Dwyer (KM)

School of Medicine, Faculty of Health, Deakin University, Geelong, Australia.

Pedro C Cavadas (PC)

Plastic and Reconstructive Surgery Division, Clinica Cavadas, Valencia, Spain.

Alessandro Thione (A)

Plastic and Reconstructive Surgery Division, Clinica Cavadas, Valencia, Spain.

Brendan Clarke (B)

Department of Plastic and Reconstructive Surgery, Leeds General Infirmary, Leeds, United Kingdom.

Simon Kay (S)

Department of Plastic and Reconstructive Surgery, Leeds General Infirmary, Leeds, United Kingdom.

Dan Wilks (D)

Department of Plastic and Reconstructive Surgery, Leeds General Infirmary, Leeds, United Kingdom.

Subramania Iyer (S)

Plastic/Reconstructive Surgery, Amrita Institute of Medical sciences, Kochi, Kerala, India.

Martin Iglesias (M)

Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," Mexico City, Mexico.

Ömer Özkan (Ö)

Department of Plastic and Reconstructive Surgery, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Özlenen Özkan (Ö)

Department of Plastic and Reconstructive Surgery, Akdeniz University Faculty of Medicine, Antalya, Turkey.

Johanna Krapf (J)

Department of Plastic and Reconstructive Surgery, Innsbruck Medical University, Innsbruck, Austria.

Annemarie Weissenbacher (A)

Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Nuffield Department of Surgical Sciences, Oxford Transplant Centre, Churchill Hospital, Oxford University, Oxford, United Kingdom.

Palmina Petruzzo (P)

Department of Transplantation, Hôpital Edouard Herriot, HCL, Lyon, France.

Stefan Schneeberger (S)

Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH